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M.M. Elahi,1* G.K. Chetty,1 R. Kirke,1 T. Azeem,2 R. Hartshorne1 and T.J. Spyt1Departments of 1Cardiothoracic Surgery, and 2Cardiology, Glenfield Hospital, Groby Road,
Leicester LE3 9QP, UKBackground. Our centre in 1995 reported 26% of vascular complications in cardiac surgical patients treated with intra-aortic
balloon pump (IABP). However, during the last decade there have been improvements in IABP technology and insertion
techniques. We aimed to evaluate the impact of these changes on the incidence of IABP-related complications in cardiac surgery.
Methods. Demographics, indications, technique and complication rate in 186 consecutive patients treated with IABP from
January 1994 to December 1998 (Group I) were compared with 323 consecutive patients treated with IABP from January
1999 to December 2003 (Group II) at our regional cardiothoracic centre. Data was variably expressed as mean with or
without range and either standard deviation or range. Statistical significance was accepted at P!0.05.
Results. There were 121 (65%) and 194 (60%) males in Group I and II, respectively. The mean age was 66G12.1 (17–88)
years and the mean duration of IAPB use was 43.5 h (range 3–144 h). Overall complication rate was 10% in Group I and
2% in Group II whereas vascular complications accounted for 3% in Group-I and 1% in Group-II. Logistic regression
analysis demonstrated cardiogenic shock being strongly correlated to in-hospital mortality (OR 4.68; PZ0.004) followed by
older age (OR 3.12; PZ0.034) and ejection fraction !35% (OR 1.78; PZ0.03).
Conclusion. The study demonstrated a significant decrease in the IABP-related complications even though complexity of
cases referred for surgery has increased. Henceforth, the risk of 1% vascular complications should play little influence on
decision-making regarding the use of IABP.Keywords: Intra-aortic balloon pump; Cardiac surgery; Trauma; Management.Introduction
The indications for the use of intra-aortic balloon
pump (IABP) in cardiac surgery include inability to
wean the patient from cardiopulmonary bypass (CPB),
post-operative low cardiac output syndrome, intract-
able ventricular arrhythmias and occasionally as a
prophylactic use in patients with unstable symptoms
or associated with poor ventricular function.1 Previous
studies have demonstrated that the augmented dias-
tolic pressure results in a redistribution of coronary
blood flow towards ischaemic areas of the myocar-
dium, hence an improved myocardial supply/
demand balance.2,3 After load is reduced and diastolic
pressure augmented, resulting in an increased stroke
volume and cardiac output.4
Although technical advances such as percutaneousing author. Dr Maqsood Elahi, Department of Cardio-
ery, Glenfield Hospital, Groby Road, Leicester LE3 9QP,
: Maqsood@doctors.org.uk
0591+ 04 $35.00/0 q 2005 Elsevier Ltd. All rights reserinsertion;5 smaller diameter catheters6 and sheathless
insertion7 have simplified the use of IABP and made it
more user friendly to cardiologists and cardiac
surgeons, the published IABP-related complication
rate (7.2–47%) still remains significantly high.8–10 An
earlier report from our centre identified peripheral
vascular disease (PVD), female gender and diabetes as
significant predictors and demonstrated high rate of
vascular complications (26%) in post-surgical cardiac
patients.11 However, this study lacked in evaluating
various other factors that might have led to compli-
cations associated with its use.12
Hence, the aim of this study was to evaluate the
variations in the IABP insertion technique and its
impact on the complication rate over a 10-year period
in our centre.Methods
Indications, technique and complication rate in 186
consecutive patients treated with IABP from JanuaryEur J Vasc Endovasc Surg 29, 591–594 (2005)
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M. M. Elahi et al.5921994 to December 1998 (Group I) were compared with
323 consecutive patients treated with IABP from
January 1999 to December 2003 (Group II) at the
regional cardiothoracic centre. Their base-line demo-
graphics, clinical data, assessment of the lower limbs,
haemodynamic status and pertinent medications were
available from their respective case notes. The IABP
(Datascope Corporation, Oakland, New Jersey, USA)
was inserted via the femoral artery in the groin either
pre, intra or post-operatively. The IABP inserted
percutaneously (Seldinger technique) were removed
without exposure of the femoral artery and bleeding
controlled by direct pressure. Those, which had been
inserted by open technique, were removed by re-
exposure of the femoral artery and direct repair of the
arteriotomy using 5.0 polypropylene (Ethicon Inc,
USA) on the intensive care unit (ICU). There was no
difference observed in evaluating complications
associated with how the IABP was inserted though
this to some degree reflected indications for use. We
collected data based on the following endpoints:†EuLimb ischaemia: decreased arterial flow as mani-
fested by diminished pulse on flow Doppler that
resolved following balloon removal, loss of sen-
sation, abnormal limb temperature; or complication
requiring surgical intervention.† Bleeding: resulting in groin haematomas or con-
tinuous oozing from the puncture site.† All-cause hospital mortality occurring from any
cause during IABP or after IABP and the following
variables were compared:
Demography and patient characteristics including
age, sex, height, weight, diabetic status, PVD, previous
myocardial infarction or CABG; indications for IABP
insertion; catheter size and approach; concomitant use
of anticoagulants and IABP related complications.Statistics
Data was variably expressed as mean with or without
range and either standard deviation or range. Where
appropriate, statistical analysis was performed using
logistic regression method, Chi-square test to compare
categorical variables and Student’s t test for continu-
ous variables. Statistical significance was accepted at a
level of P!0.05.Results
The patients’ demographics and indications for ther J Vasc Endovasc Surg Vol 29, June 2005use of IABP in Group-I and Group-II are summarized
in Table 1. There were 121 (65%) and 194 (60%) males
in Group I and II, respectively. The mean age was 66G
12.1 (17–88) years and the mean duration of IAPB use
was 43.5 h (range 3–144 h). Overall complication rate
was 10 vs 2% in Group I and Group II, respectively,
and in-hospital mortality was 8%, however, the
mortality rate was only 0.007% as a direct consequence
of IABP. In our series, 96% of IABPs were inserted
percutaneously. IABP related vascular complications
accounted for 3% in Group-I and 1% in Group-II.
There were, however, significant differences between
the two groups in terms of peripheral vascular disease,
useof anticoagulants, sizeand typeof catheters (Table1).
The indications for use revealed interesting differences
between the two groups with regards to its greater
prophylactic use in cardiogenic shock in later years
(1998–2003). Groin haematoma (3 vs 0.6%; P!0.001),
limb ischaemia (2 vs 0%; P!0.01) and femoral artery
trauma (4 vs 0.6%; P!0.001) were the attributable
complications of IABP, significantly higher in Group-I
as compared to Group-II (Table 2). Other compli-
cations included infection (0.2%), compartment syn-
drome (1%) and below knee amputation (0.1%).
Multiple logistic regression analysis among patients
supported by the IABP revealed risk factors for limb
ischaemia, bleeding and in hospital mortality (Table 3).
Female gender, associated PVD, and sheathed cath-
eters with size O8.0 French were strongly associated
with limb ischaemia. Access site bleeding occurred in
4% of case. The risk for bleeding included female
gender, sheathed catheters, open femoral cut tech-
niques and older age group (Table 3). Cardiogenic
shock remained strongly correlated to in-hospital
mortality (OR 4.68; PZ0.004) followed by older age
(OR 3.12; PZ0.034) and ejection fraction !35% (OR
1.78; PZ0.03). With regard to in-hospital mortality, no
significant differences were detected between the two
groups.Discussion
IABP is an effective mean of supporting the failing
circulation in patients at high risk of cardiovascular
events post-operatively. However, the use of IABP is
not without complications, rates as high as 47% have
been reported.8–10 This may relate to several consider-
able factors such as techniques used during insertion
and indiscriminate use of anticoagulants in the
absence of agreed protocol for anticoagulation for
IABP. We have, therefore, examined various aspects of
the procedure at our regional centre and compared
Table 1. Clinical and demographic characteristics
Variables Group I (NZ186) Group II (NZ323) P-value
Age (years) mean 65.9G11.7 (20–88) 66.3G12.3 (17–75) 0.899
Sex (M/F) 121/65 194/129 0.234
Angina status (CCS)
CCS 3 19 (10%) 45 (14.0%) 0.56
CCS 4 14 (7.5%) 20 (6.2%) 0.54
Dyspnoea status (NYHA)
NYHA 3 56 (30.1%) 128 (39.6%) 0.23
NYHA 4 32 (17.2%) 39 (12.0%) 0.345
Ejection fraction!30–40% 18 (9.7%) 38 (11.7%) 0.78
Myocardial infarction 22 (11.8%) 43 (13.4%) 0.14
Diabetes mellitus (DM) 15 (8.1%) 33 (10.2%) 0.43
Hypercholesteremia 53 (28.5%) 99 (30.7%) 0.56
Creatinine (mmol/l)O200 5 (2.5%) 9 (2.8%) 0.76
Redo operation sequence 17 (9.1%) 51 (15.8%) 0.023
Operative priority (urgent) 27 (14.5%) 94 (29.1%) 0.01
Peripheral vascular disease 34 (18.2%) 120 (37.2%) 0.014
Preop use in high risk patients 8 (4.4%) 44 (13.6%) 0.021
Weaning from CPB 24 (12.9%) 43 (13.3%) 0.45
Cardiogenic shock 8 (4.30%) 46 (14.2%) 0.034
Anticoagulants 105 (56.5%) 284 (87.9%) 0.05
Size of catheter (!9.5 French) 57 (30.6%) 248 (76.8%) 0.009
Type of catheter (sheathless) 44 (23.6%) 305 (94.4%) 0.014
Approach (percutaneous) 176 (94.6%) 308 (95.4%) 0.78
Mean duration of IABP (hour) 43.0 (13–144) 42 (3–110) 0.82
Overall complications rate (%) 9.9 2.32 0.021
Vascular complications (%) 2.99 1.08 0.045
Table 3. Risk factors for cardiac surgery patients in which IABP
used
Variables Risk factors OR P-value
Groin haematoma Female 1.26 0.034
Complications Attributable to IABP 593them between two 5-year cohorts of patients for whom
data was available.
Until 1998, our centre was using 9.5 French IABP
catheters with sheaths being used to secure access to
the femoral artery. The use of IABP increased
dramatically at an average of 15/year in 1994–1995
to 52/year in 2002–2003 by the surgeons at our
regional centre in the background of its likelihood
that pre-operative IABP insertion was associated with
better survival. This is in agreement with the reported
studies.5–7 This may also be attributed to the nature of
cardiac surgical patients being referred in the current
era compared to previous years, perhaps because
cardiological intervention has considerably increased
which tends to cater one or two artery disease cases.
Weaning of patients from cardiopulmonary bypass
remains an important use of IABP, although expand-
ing indications include its use to support high-risk
patients with refractory ventricular failure, mechanical
complications due to myocardial infarction, ischaemiaTable 2. IABP attributable complications
Variables Group I
(NZ186)
Group I
(NZ323)
P-value
Groin haematoma 6 (3.22%) 2 (0.62%) 0.03
Compartment syndrome 2 (1.07%) 0 (0.0%) 0.89
Limb ischaemia 4 (2.13%) 0 (0.0%) 0.023
Femoral artery trauma 7 (3.76%) 0 (0.0%) 0.01
Infection 1 (0.5%) 0 (0.0%) 0.78
Amputation 0 (0.00%) 0 (0.0%) 0.63related intractable ventricular arrhythmia, unstable
refractory angina and cardiogenic shock.
The current study demonstrated a significantly
lower rate of vascular complications associated with
the use of IABP, in contrast to our earlier report.11 This
difference may merely reflect the increased use of
smaller size balloon catheters, sheathless insertion
techniques and percutaneous approach in the last 10
years at our centre. The importance of frequent use of
IABP and, therefore, experience with their use should
not be under-estimated. Evaluation of risks and
benefits associated with prophylactic use of IABP,
low molecular weight heparin and careful lower limb
assessment before, during, and after counterpulsation
using either with Doppler ultrasound; oxygenSheathed 1.56 0.012
Femoral cut-down 3.64 0.014
Age 2.14 0.0134
Limb ischaemia Female 2.79 0.021
PVD 2.35 0.009
Sheathed 1.97 0.043
O8.0 French 3.79 0.0023
Ejection fraction!35% 0.89 0.03
In hospital mortality cardiogenic shock 4.68 0.004
Age O65 3.12 0.034
Ejection fraction!35% 1.78 0.03
Urgent operation 1.34 0.023
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the complications associated with this device. Diag-
nosis of lower limb ischaemia in an unconscious,
ventilated, cardiovascularly compromised patient can
be difficult but diligent observation of the limb, serial
use of Doppler together with prompt referral and close
liaison with the vascular team has improved the
outcome.
Cardiogenic shock remains the leading cause of
death in our series. Even with successful coronary
reperfusion, patient mortality has remained high. Few
studies, however, have evaluated the relationship
between cardiogenic shock and clinical outcome in
patients with IABP support.13 It is now clear that the
cause of shock in patients with myocardial infarction is
myocardial ischaemia and it has been suggested that
the survival of patients with cardiogenic shock
complicatingmyocardial infarction could be improved
by coronary revascularisation following a period of
IABP support. Recently, randomised studies have
attempted to test whether emergency revascularisa-
tion does indeed improve survival in patients with
cardiogenic shock complicating myocardial infarction
but their data instead highlighted the limitations of
coronary revascularisation.14 Hence, cardiogenic
shock must be treated more aggressively even if
coronary revascularisation is successful, because with-
out improvement in the shock state, the prognosis
tends to be poor. Given that, the present study is a
post-hoc analysis of prospectively gathered data and
not a randomised one, the decision regarding deploy-
ment of IABP was left up to the cardiology/cardiac
surgical team.
In conclusion we observed a significant decrease in
vascular complications rate attributed to IABP
between the two 5-year periods because of the
significant increase in the number of IABP used.
Evolving technology in balloon design, less invasive
deployment techniques and appropriate anticoagula-
tion therapy may have contributed to these encoura-
ging results. We envisage an increase in the complexity
of cardiac cases referred for surgery in the coming
years and, therefore, expect even greater use of this
cardiac support device. We believe that the decision to
use IABP should not be influenced by a concern over
the risk of vascular complications and will allow
surgeons to safely extend its benefits to high risk
patients to avoid haemodynamic instability that
otherwise, often occurs.Eur J Vasc Endovasc Surg Vol 29, June 2005Acknowledgements
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